"Clinical drug trials in Ukraine: Myths and realities", September 2013

The main conclusion to be drawn is that not only patients, but also pharmaceutical manufacturers, should thoroughly analyse whether or not the legislative regulations are being properly met. From a corporate behaviour perspective, carrying out studies on one or more children, including orphans – who need even more protection as vulnerable subjects – in a context of weak ethical supervision and regulatory mechanisms, is irresponsible.